跳至主要内容
临床试验/NCT04140201
NCT04140201Unknown4 期

Evaluation of Lipid Lowering Agents on Diabetic Retinopathy and Cardiovascular Risk of Diabetic Patients

Alaa Hassan ElBaz0 个研究点目标入组 80 人开始时间: 2020年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
发起方
入组人数
80
主要终点
The 80 participants will be evaluated through reduction of macular edema

研究概览

简要总结

The investigator study evaluate the effect of different lipid lowering agents on the progression of diabetic retinopathy and other reduction of cardiovascular risk of diabetic patients

详细描述

The investigator study compare the effect of lipid lowering agent on the enhancement of visual acuity and on reduction of macular edema in patients with diabetic retinopathy and also compare their effect on reduction of cardiovascular risk on diabetic patients via assessment of ASCVD risk score

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • type 2diabetes
  • Non proliferative diabetic retinopathy

排除标准

  • Uncontrolled glycemic level
  • proliferative diabetic retinopathy

研究组 & 干预措施

Receive oral hypoglycemic +fibrate

Active Comparator

Fenofibrate +standard treatment

干预措施: Fenofibrate 200mg (Drug)

Receive oral hypoglycemic +omega 3

Active Comparator

Eicosapentanoic acid + standard treatment

干预措施: Omega 3 fatty acid (Drug)

Receive oral hypoglycemic +statin

Active Comparator

Simvastatin + standard treatment

干预措施: Simvastatin 40mg (Drug)

结局指标

主要结局

The 80 participants will be evaluated through reduction of macular edema

时间窗: 18 weeks

assessed by ocular coherence tomography

次要结局

  • The 80 participants will be evaluated through reduction of cardiovascular risk(18 weeks)

研究者

发起方
Alaa Hassan ElBaz
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Alaa Hassan ElBaz

Assistant lecturer at beni suef university

Beni-Suef University

相似试验